title: Effects of lithium and valproate on oxidative stress and behavioral changes induced by administration of m-AMPH.
abstract: In the last years our research group has studied and validated the animal model of mania induced by dextroamphetamine (d-AMPH). Considering the lack of animal models of mania reported in the literature; this study evaluated the possibilities to validate the animal model induced by methamphetamine (m-AMPH). Then, we evaluated the effects of lithium (Li), valproate (VPA) on the behavior and parameters of oxidative damage in rat brain after administration of m-AMPH. In the prevention treatment, Wistar rats were pretreated with Li, VPA or saline (Sal) for 14 days, and then, between days 8 and 14, rats were treated with m-AMPH (1, 0.5 or 0.25 mg/kg) or Sal. In the reversal treatment, rats were first given m-AMPH (0.25 mg/kg) or Sal. Locomotor behavior was assessed using the open-field task and parameters of oxidative damage were measured in brain structures. Our results show that the hyperactivity was prevented and reverted by Li and VPA only when m-AMPH was administered in the dose of 0.25mg/kg. In addition, the m-AMPH in all doses administrated induced oxidative damage in both structures tested in two models. Li and VPA reversed and prevented this impairment, however in a way dependent of cerebral area, the dose of m-AMPH and technique.
authors.affiliation: Laboratory of Neurosciences and National Institute for Translational Medicine, Postgraduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, 88806-000 Criciúma, SC, Brazil.
authors.forename: Dayane D
authors.initials: DD
authors.lastname: da-Rosa
authors.forename: Samira S
authors.initials: SS
authors.lastname: Valvassori
authors.forename: Amanda V
authors.initials: AV
authors.lastname: Steckert
authors.forename: Felipe
authors.initials: F
authors.lastname: Ornell
authors.forename: Camila L
authors.initials: CL
authors.lastname: Ferreira
authors.forename: Jéssica
authors.initials: J
authors.lastname: Lopes-Borges
authors.forename: Roger B
authors.initials: RB
authors.lastname: Varela
authors.forename: Felipe
authors.initials: F
authors.lastname: Dal-Pizzol
authors.forename: Monica L
authors.initials: ML
authors.lastname: Andersen
authors.forename: João
authors.initials: J
authors.lastname: Quevedo
mesh_terms: D000818:Animals; D018692:Antimanic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control / Q000523:psychology; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D018020:Lithium Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008694:Methamphetamine; D009043:Motor Activity / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects*; D050050:Protein Carbonylation / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014635:Valproic Acid / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D018692:Antimanic Agents; D018020:Lithium Compounds; D017392:Thiobarbituric Acid Reactive Substances; D008694:Methamphetamine; D014635:Valproic Acid